Experts say 'plan early on how your product will be used to help you solve R&D challenges' ... and much more when the team spoke to him in the run-up to our webinar covering this.
The team spoke to Dr Matthew Goodman, Medical Director at Xylem Medical to learn why early-stage biopharma, medical device or health-tech businesses need Medical Affairs. Read on to discover how to avoid (and fix!) common issues by introducing Medical Affairs into your business. And, most importantly, why it plays a vital role in supercharging the value of your product and business valuation:
Common problems in R&D
Your focus on research and development can be all consuming. That’s understandable. It’s at the forefront of your day-to-day plans. But it means that other things like product launches and marketing are pushed aside for consideration into the future … perhaps even into the background … as you work to meet technical challenges.
The problem this causes is that your current decisions will have a massive impact on value and the potential to be had for patients, prescribers/payors and future investors.
How Medical Affairs provides a fix
Planning ahead now (even with lite-touch support on Medical Affairs) on how your product will be used in real life will help you reap rewards in solving the R&D challenges you face. It’ll also help you being on the front foot with potential funding issues.
By being proactive in planning ahead you ensure the best product positioning and optimal value of your assets.
FREE WEBINAR Why early-stage Biotech’s need Medical Affairs 12/1/22 10 am
Join us for a deep dive into how early-stage life science R&D businesses benefit from early and light-touch Medical Affairs support and how that's best done at our webinar on 12th January 2022, 10 - 10.45 am where we’ll live interview Dr Matthew Goodman for the answers.
Click here to Book my spot